ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG
Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.
Others
Patients who have a combination of cardiovascular disease such as severe organic valvular disease.
Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.
Others